Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Travoprost is absorbed through the cornea and is hydrolyzed to the active free acid. Data from four multiple dose pharmacokinetic studies using travoprost ophthalmic solution, 0.004%(totaling 107 subjects) have shown that plasma concentrations of the free acid are below 0.01ng/mL (the quantitation limit of the assay) in two-thirds of the subjects. In those individuals with quantifiable plasma concentrations (N=38), the mean plasma Cmax was 0.018 ± 0.007ng/mL (ranged 0.01 to 0.052 ng/mL) and was reached within 30 minutes. From these studies,travoprost is estimated to have a plasma half-life of 45 minutes. There was no difference in plasma concentrations between Days 1 and 7, indicating steady-state was reached early and that there was no significant accumulation.

none

Pregnancy Category C

A study in lactating rats demonstrated that radiolabeled travoprost and/or its metabolites were excreted in milk. It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IZBA is administered to a nursing woman.

Ocular hyperemia, decreased visual acuity, eye discomfort, foreign body sensation, pain, and itching; increased pigmentation (ie, brown) to iris, eyelid, and eyelashes; eyelash changes(eg, increased length, color)

One drop in the affected eye(s) once daily in the evening.
建議用量為每天晚上於罹病的眼睛滴入一滴藥水。
由於過往經驗顯示較頻繁使用前列腺素類似物可能使降眼壓效果減弱，因此 IZBA（travoprost 點眼液）0.003% 使用頻率不得超過每天一次。

Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long term chronic use.

請保存於 30°C以下